Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer
- PMID: 31208693
- DOI: 10.1016/j.trecan.2019.04.003
Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer
Abstract
In two recent articles, Kinsey et al. (Nature Medicine 2019;25:620-627) and Bryant et al. (Nature Medicine 2019;25:628-640) reported that inhibition of MEK-ERK signaling in KRAS-mutated cancers induced autophagic flux, presumably as a metabolic adaptation mechanism. Importantly, they demonstrated that autophagy blockade via chloroquine (CQ) or hydroxychloroquine (HCQ) enhanced the efficacy of MEK-ERK inhibition in various preclinical models of KRAS-driven cancers, providing a rational basis for future clinical evaluation of this combination therapy.
Keywords: AMPK; KRAS; MEK inhibitor; autophagy; metabolism.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833748 Free PMC article.
-
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833752 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
